Sign In
Buy MRNA
$49.06
+3.42 (+7.49%)
At Close: Jun 03, 2026
What Is Going On With Moderna Stock?
09:25am, Thursday, 13'th Nov 2025
Moderna (MRNA) stock has reached day 5 of a consecutive winning streak, with total gains during this time reaching a 13% return. The company's value has increased by approximately $1.2 billion over th
Acadian Asset Management LLC Purchases 477,072 Shares of Moderna, Inc. $MRNA
03:48am, Wednesday, 12'th Nov 2025
Acadian Asset Management LLC lifted its position in Moderna, Inc. (NASDAQ: MRNA) by 284.8% in the undefined quarter, according to its most recent Form 13F filing with the Securities and Exchange Commi
Telemark Asset Management Builds Position in Beaten-Down Biotech Stock.
12:59pm, Monday, 10'th Nov 2025
Initiated stake: 500,000 shares, an estimated $12.91 million increase Post-trade Moderna position: 500,000 shares, valued at $12.91 million Moderna now accounts for 1.23% of Telemark's reportable AUM,
Moderna (MRNA) Reports Q3 Earnings: What Key Metrics Have to Say
11:30pm, Thursday, 06'th Nov 2025
The headline numbers for Moderna (MRNA) give insight into how the company performed in the quarter ended September 2025, but it may be worthwhile to compare some of its key metrics to Wall Street esti
Moderna, Inc. (MRNA) Q3 2025 Earnings Call Transcript
03:26pm, Thursday, 06'th Nov 2025
Moderna, Inc. ( MRNA ) Q3 2025 Earnings Call November 6, 2025 8:00 AM EST Company Participants Lavina Talukdar - Senior VP & Head of Investor Relations Stéphane Bancel - CEO & Director James Mock - C
Moderna Inc (MRNA) Q3 2025 Earnings Call Highlights: Strategic Cost Reductions Amid Revenue Challenges
02:11pm, Thursday, 06'th Nov 2025
Revenue: $1 billion for Q3 2025.Net Loss: $200 million for Q3 2025.Cash and Investments: $6.6 billion at the end of Q3 2025.Cost Reduction: 34% reduction in co
Moderna Q3 Earnings Beat, Stock Up on Revised '25 Spending Plans
01:01pm, Thursday, 06'th Nov 2025
Moderna MRNA incurred a loss of 51 cents per share in the third quarter of 2025, narrower than the Zacks Consensus Estimate of a loss of $2.15. In the year-ago period, the company had reported earnin
mRNA Vaccine Maker Moderna Lowers R&D Spending, Tightens Sales Forecast
12:29pm, Thursday, 06'th Nov 2025
Moderna Inc. (NASDAQ:MRNA) reported a third-quarter loss of 51 cents, beating the expected loss of $2.02, a turnaround from an income of 3 cents a year ago.
Moderna (MRNA) Reports Q3 Loss, Tops Revenue Estimates
09:15am, Thursday, 06'th Nov 2025
Moderna (MRNA) came out with a quarterly loss of $0.51 per share versus the Zacks Consensus Estimate of a loss of $2.15. This compares to earnings of $0.03 per share a year ago.
Moderna Inc (MRNA) Q3 2025 Earnings: EPS of $(0.51) Beats Estimate, Revenue Surpasses Expectations at $1.0 Billion
07:32am, Thursday, 06'th Nov 2025
Revenue: Reported $1.0 billion for Q3 2025, surpassing the estimated $886.54 million.Net Loss: Recorded a GAAP net loss of $200 million, a significant shift fr
Moderna trims top end of full-year forecast on weak COVID vaccine sales
07:11am, Thursday, 06'th Nov 2025
Moderna lowered the top end of its 2025 revenue forecast by $200 million on Thursday, citing weaker-than-expected sales of its COVID-19 vaccine in the U.S. as Americans struggled to access the shots.
Moderna Swings to a Loss on Fewer Covid-19 Vaccine Sales
07:09am, Thursday, 06'th Nov 2025
Moderna swung to a loss and logged lower sales in the third quarter as it works to expand its offerings amid weakening demand for its Covid-19 vaccine.
Moderna Reports Third Quarter 2025 Financial Results and Provides Business Updates
07:00am, Thursday, 06'th Nov 2025
Reports third quarter revenue of $1.0 billion, GAAP net loss of $(0.2) billion and GAAP EPS of $(0.51) Narrows 2025 projected revenue range to $1.6 - $2.0 billion Improves 2025 expected GAAP operating
Should You Buy Moderna Stock Ahead of Q3 Earnings Report?
09:41am, Tuesday, 04'th Nov 2025
MRNA is likely to have faced earnings pressure and pipeline setbacks as waning COVID-19 vaccine demand weighs on its outlook.
Bessemer Group Inc. Sells 3,655 Shares of Moderna, Inc. $MRNA
04:03am, Tuesday, 04'th Nov 2025
Bessemer Group Inc. lessened its holdings in Moderna, Inc. (NASDAQ: MRNA) by 31.5% in the second quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 7,949
